You just read:

Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult Patients

News provided by

Orexigen Therapeutics, Inc.

May 02, 2016, 08:30 ET